STOKHIGH SIGNALOPPORTUNITY10-K

STOK has successfully progressed zorevunersen from Phase 1/2a to an active Phase 3 trial with patients enrolled, while achieving a dramatic financial turnaround including 405% revenue growth and positive operating cash flow.

The company has executed a critical milestone by moving their lead drug candidate zorevunersen into Phase 3 trials with actual patient dosing completed and enrollment progressing toward completion in Q2 2026. The shift in strategic language from "focus on rapid execution" to "deliver zorevunersen to patients as quickly as possible" signals increased confidence in commercial viability, supported by their plan to initiate rolling NDA submission in H1 2027.

Comparing 2026-03-16 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

STOK delivered exceptional financial performance with revenue surging 405% to $184.4M and operating cash flow turning positive at $45.6M from negative $86.9M, representing a remarkable $132.5M improvement. While R&D expenses increased 55% to $137.9M reflecting the Phase 3 trial costs, the company's net loss narrowed dramatically by 92% to just $6.9M, and total assets grew 54% to $418.4M, indicating strong capital positioning to fund operations through the critical Phase 3 completion and NDA submission phases.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+404.5%
$36.6M→$184.4M

Strong top-line growth of 404.5% — accelerating demand or successful expansion into new markets.

Accounts Receivable
Balance Sheet
+255.9%
$1.7M→$5.9M

Receivables surged 255.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Capital Expenditure
Cash Flow
+230%
$203K→$670K

Capital expenditure jumped 230% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
+152.5%
-$86.9M→$45.6M

Operating cash flow surged 152.5% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+92.3%
-$89.0M→-$6.9M

Net income grew 92.3% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+79.7%
-$101.4M→-$20.6M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Interest Expense
P&L
-65.4%
$26K→$9K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Total Liabilities
Balance Sheet
+55.1%
$42.5M→$66.0M

Liabilities grew 55.1% — significant increase in debt or obligations, assess impact on financial flexibility.

R&D Expense
P&L
+54.7%
$89.1M→$137.9M

R&D investment increased 54.7% — signals commitment to future product development, though near-term margin impact.

Total Assets
Balance Sheet
+54.1%
$271.6M→$418.4M

Asset base grew 54.1% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-18
ADDED
Zorevunersen is currently being evaluated in our global Phase 3 clinical study, EMPEROR, which was initiated in May 2025 , with the first patient dosed in August 2025..
We expect to complete enrollment of approximately 150 patients in the second quarter of 2026, with pivotal Phase 3 data anticipated in mid-2027 to support the submission of a New Drug Application ( NDA ) to the U.S.
We plan to initiate a rolling NDA submission in the first half of 2027.
This trial follows the completion of two open-label Phase 1/2a studies, MONARCH in the United States and ADMIRAL in the United Kingdom, and further evaluates the efficacy and safety of zorevunersen in children and adolescents ages 2 to up to 18 with Dravet syndrome.
The critical pillars of our strategy include: Deliver zorevunersen to patients as quickly as possible .
+7 more — sign up free →
REMOVED
Food and Drug Administration ( FDA ), European Medicines Agency ( EMA ), and Japan s Pharmaceuticals and Medical Devices Agency ( PMDA ), a Phase 3 study, EMPEROR, is expected to begin in the second quarter of 2025 to further evaluate efficacy and safety of zorevunersen in children and adolescents ages 2 to up to 18 with Dravet syndrome.
We have completed Phase 1/2a clinical trials for zorevunersen.
The critical pillars of our strategy include: Focus on rapid and effective execution of the Phase 3 clinical trial.
In addition, due to zorevunersen being granted Breakthrough Therapy Designation in the U.S., we have access to more intensive guidance from the FDA, which may help to expedite development.
Furthermore, we believe the announcements of Breakthrough Therapy Designation, recent clinical updates and regulatory alignment with the FDA, EMA and PMDA have catalyzed the Dravet syndrome community, and we have carefully selected and engaged with clinical sites to efficiently recruit patients.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
IRIXHIGHIRIX demonstrated a dramatic operational turnaround with revenue surging 283% wh...
2026-04-02
CSAIHIGHCSAI underwent a dramatic financial transformation with revenue growing 271% to ...
2026-03-31
PLMKWHIGHPLMKW has entered into a definitive business combination agreement with Controll...
2026-03-31
LXEOHIGHLXEO achieved significant clinical milestones with positive interim data and reg...
2026-03-30
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →